3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Conditions
Prostatic Neoplasms
240
Neoplasm Metastasis
20
Neoplasms
11
Prostatic Neoplasms, Castration-Resistant
7
Prostate Cancer Metastatic
7
Metastatic Castration-resistant Prostate Cancer
5
Pain
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Metastatic Castration-Resistant Prostate Cancer
3
Testicular Neoplasms
2
Primary Myelofibrosis
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pdgfra-Associated Chronic Eosinophilic Leukemia
2
Myeloproliferative Disorders
2
Multiple Myeloma
2
Metastatic Castration Resistant Prostate Cancer
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Neutrophilic, Chronic
2
Leukemia, Myelomonocytic, Juvenile
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
2
Leukemia, Myeloid, Accelerated Phase
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Kidney Neoplasms
2
Interventions
pembrolizumab
26
lenvatinib
7
belzutifan
5
Saline Solution
4
Docetaxel
4
epacadostat
3
enzalutamide
3
enfortumab vedotin
3
Surgical Procedures, Operative
3
Prednisone
3
Gemcitabine
3
Cisplatin
3
Paclitaxel
2
Dexamethasone
2
Calcium Dobesilate
2
vinflunine
1
pazopanib
1
olaparib
1
Sunitinib
1
Prednisolone
1
Oxaliplatin
1
Fluorouracil
1
Cystectomy
1
Carboplatin
1
Capecitabine
1
CB-1158
1
Bevacizumab
1
Axitinib
1
Albumin-Bound Paclitaxel
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Prednisone
×
Genitourinary
×
Clear all
NCT03834506
2025-07-18
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3
Completed
1,030 enrolled
24 charts
NCT03834519
2025-05-18
KEYLYNK-010
Merck Sharp & Dohme LLC
Phase 3
Completed
793 enrolled
23 charts
NCT04907227
2024-07-12
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3
Terminated
81 enrolled
19 charts